Cost-effectiveness and carbon footprint of cystoscopic surveillance schedules in non-muscle-invasive bladder cancer
Abstract Repeated cystoscopy for non-muscle-invasive bladder cancer incurs costs and greenhouse-gas emissions, but fewer examinations may delay recurrence detection. We compared nine surveillance schedules in a 15-year monthly cohort model stratified by European Association of Urology risk group. We used 2021 United States costs and an international emissions inventory. In low-risk patients, ending scheduled surveillance after the three-month examination, while retaining investigation of symptoms, reduced modelled costs by 24.0% and inventoried emissions by 13.0% compared with guideline follow-up. Time spent with undetected recurrence increased. In 5,000 paired simulations, the mean difference in quality-adjusted life-years for this low-risk comparison was 0.009 per patient (95% uncertainty interval, -0.260 to 0.291). Clinical results depended on progression before recurrence detection and diagnosis prompted by symptoms; less favourable assumptions increased progression and bladder-cancer deaths. Recurrence treatment accounted for most inventoried emissions, limiting the carbon savings from fewer cystoscopies. Selected reductions in low-risk surveillance warrant prospective evaluation, but the model does not establish the safety of stopping scheduled surveillance after one examination.
Authors
- Chunxiao Yu
Institutions
- Zaozhuang Municipal Hospital (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-15
- DOI
- https://doi.org/10.1038/s41598-026-79726-1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00